Vaccine against Hepatitis A virus (HAV) is part of the routine vaccination schedule in Israel since 1999. As of 2016, new recruits to the Israel Defense Forces should have been vaccinated in their childhood. This sero-survey aimed to determine immunity against HAV 18 years after childhood vaccination, and to re-evaluate the need for HAV vaccination booster upon recruitment. Two populations were studied: soldiers who were recruited during 2011-2012, who belonged to birth cohorts before childhood vaccination (BCV) was introduced; and recruits from 2017, who belonged to birth cohorts after childhood vaccination (ACV) was introduced. Data on 339 BCV recruits and 295 ACV recruits were analyzed. Seropositivity was 35% in the BCV group and 68% in the ACV group (P < 0.0001). Seropositivity rates among ACV subjects enable evaluation of the vaccination program's impact on the population. Our findings do not support discontinuation of HAV vaccination of at risk groups until further evaluation.

中文翻译：

---

在将灭活疫苗引入常规儿童疫苗接种计划 18 年后，以色列人群对甲型肝炎病毒的血清保护作用。

自 1999 年以来，针对甲型肝炎病毒 (HAV) 的疫苗是以色列常规疫苗接种计划的一部分。截至 2016 年，以色列国防军的新兵本应在童年时期接种疫苗。该血清调查旨在确定儿童接种疫苗 18 年后对 HAV 的免疫力，并在招募时重新评估对 HAV 疫苗接种加强剂的需求。研究了两个人群：2011-2012 年招募的士兵，在引入儿童疫苗接种 (BCV) 之前属于出生队列；和 2017 年招募的新兵，他们在引入儿童疫苗接种 (ACV) 后属于出生队列。分析了 339 名 BCV 新兵和 295 名 ACV 新兵的数据。BCV 组的血清阳性率为 35%，ACV 组为 68%（P < 0.0001）。ACV 受试者的血清阳性率有助于评估疫苗接种计划对人群的影响。我们的研究结果不支持在进一步评估之前停止对高危人群进行 HAV 疫苗接种。